Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a -glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the -glucan to increase immunogenicity of the fungus.

Particles and related methods are disclosed.

Particles and related methods are disclosed.

Particles and related methods are disclosed.

The present invention relates to a pharmaceutical composition comprising non-decarboxylated 9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.

The present invention relates to a pharmaceutical composition comprising non-decarboxylated 9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.

The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.

The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.

The invention relates to a new combination of hyaluronic acid and macrogol, pharmaceutical compositions containing said combination and the use of the combination and compositions as laxatives.

The invention relates to a new combination of hyaluronic acid and macrogol, pharmaceutical compositions containing said combination and the use of the combination and compositions as laxatives.